secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0000950170-25-065786
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Korro Q1 net loss $23.4M; workforce reduction of 20%, cash runway into 2027
---------------------------------------------------------------------------

- Net loss $23.4M vs $19.6M YoY; collaboration revenue $2.6M from Novo Nordisk.
- Cash, cash equivalents and marketable securities $139.0M, expected to fund operations into 2027.
- Workforce reduction of approximately 20%; one-time restructuring charges ~$1.2M in Q2 2025.
- Phase 1/2a REWRITE trial interim readout for KRRO-110 expected H2 2025; trial completion in 2026.
- Expect to nominate second development candidate in 2025; Novo Nordisk cardiometabolic collaboration ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000095017025065786/0000950170-25-065786-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000095017025065786/krro-20250507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-065786

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer